Metropolis Healthcare Q2 revenue up 22.7%, PAT rises 13.2% in Q2 FY26

Metropolis Healthcare Limited reported a strong financial performance in Q2 FY26, with revenue growth of 22.7% year-on-year, reaching ₹429.2 crore compared to ₹349.8 crore in the same quarter last year. The net profit (PAT) increased by 13.2% year-on-year, amounting to ₹53 crore, up from ₹47 crore previously. The company’s earnings before interest, tax, depreciation, and amortisation (EBITDA) rose by 20.5% to ₹108.6 crore, although the EBITDA margin slightly declined to 25.3% mainly due to higher operational costs.

The growth was primarily driven by strong demand across segments, especially from preventive health check-ups and wellness offerings under the TruHealth brand, which grew about 25%. The specialty test portfolio also showed significant growth of 33-36%. Both business-to-consumer (B2C) and business-to-business (B2B) segments expanded, with revenue growing 16% and 33%, respectively. Patient and test volumes increased by approximately 11% and 12% year-on-year.

Metropolis Healthcare also benefited from strategic acquisitions like Core Diagnostics, DAPIC (Dehradun), and Scientific Pathology (Agra), which contributed to the overall results. The company remains debt-free with a net cash surplus of around ₹55 crore, focusing on margin improvements, digital channel growth, and AI-driven personalized services helping drive cross-selling and upselling.

Metropolis Healthcare has demonstrated healthy revenue and profit growth in Q2 FY26, led by its wellness and specialty segments, operational efficiency improvements, and strategic acquisitions, which underpin its market leadership in diagnostics and preventive healthcare.
MB Bureau